Biodefense Market Size, Growth Analysis and Forecast To 2030

1. Biodefense Market Size, Growth Analysis and Forecast To 2030 Biodefense Market Set to Flourish with Growing Concerns over Biological Threats The biodefense market is poised for significant growth in the coming years, driven by the increasing prevalence of infectious diseases, mounting demand in the wake of potential bioterrorist attacks, growing geopolitical conflicts, and technological advances. According to a recent report by Fairfield Market Research, the market is projected to witness an impressive compound annual growth rate (CAGR) of 6.3% from 2023 to 2030, reaching a valuation of US$24.5 billion. Access Full Report: https://www.fairfieldmarketresearch.com/report/biodefense-market The COVID-19 pandemic has shed light on the devastating consequences of biological threats, prompting governments worldwide to expand their budgets for research and development of biodefense treatments. The UK is no exception, with a growing focus on bolstering its arsenal against bioterrorism and biological warfare. As a result, the demand for biodefense products and treatments is expected to soar in the next five years. The report highlights that the anthrax segment remains a leading category in the UK biodefense market, while the "others" segment, including viruses such as influenza, cholera, Ebola, and Zika, is projected to witness the fastest growth during the forecast period, with a CAGR of 6.2%. In terms of end use, the military segment currently holds the largest share in the market, but the civil segment shows significant growth potential. North America, spearheaded by the United States, leads the global biodefense market due to favorable federal funding. However, the Asia Pacific region is expected to exhibit the

2. fastest growth through 2030. Europe, including the UK, has also increased its investment in biodefense research and development, particularly during the course of the COVID-19 pandemic. The UK government's departments, such as the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and National Institute of Allergy and Infectious Diseases (NIAID), have been instrumental in driving the country's biodefense strategies and preparedness. The UK boasts a Global Health Security (GHS) Index score of 75.9, demonstrating its high level of preparedness for threats with devastating potential. Key players in the UK biodefense market include Emergent BioSolutions, Inc., SIGA Technologies, Inc., Bavarian Nordic A/S, Altimmune, Inc., GSK plc, Sanofi Pasteur, Statera Biopharma, Inc., Xoma Corporation, Dynavax Technologies Corporation, NightHawk Biosciences, Inc., Meridian Medical Technologies, LLC, Dynport Vaccine Company LLC, Nanotherapeutics, Inc., and Soligenix. As the market becomes increasingly competitive, these companies are adopting advanced technologies and strategic collaborations to maintain their edge. Mergers and acquisitions have been witnessed in the industry, such as the merger between PharmAthene and Altimmune, as well as NightHawk Biosciences' acquisition of Elysus Therapeutics, Inc. "The UK biodefense market is poised for remarkable growth in the coming years, fueled by the escalating concerns over biological threats and the need for robust defense mechanisms," said a spokesperson from Fairfield Market Research. "With increasing investments in research and development, as well as advancements in technology, the UK is well-positioned to contribute significantly to the global biodefense industry."